Physician profile
Brooke High
NPI 1235492133
$1,282.34
in general payments reported to CMS, 2019-2025
23 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $340 · 2021: $75.23 · 2022: $49.74 · 2023: $38.43 · 2024: $60.43 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $124.99 | 2019 | |
| Allergan, INC. | $119.59 | 2019-2020 | |
| Abbvie INC. | $115.53 | 2019-2023 | |
| Exeltis, USA INC. | $109.26 | 2019-2025 | Slynd |
| Daiichi Sankyo INC. | $84.59 | 2019-2020 | |
| Conmed Corporation | $81.73 | 2019 | |
| Coopersurgical, INC. | $70.72 | 2019-2021 | |
| Sage Therapeutics, LLC | $70.27 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $62.36 | 2019-2020 | |
| Medtronic, INC. | $49.74 | 2022 | |
| Merck Sharp & Dohme LLC | $49.57 | 2019-2020 | |
| Hologic Sales and Service, LLC | $49.55 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Avion Pharmaceuticals | $40.90 | 2019-2020 | |
| Millicent US INC | $35.40 | 2020 | |
| Amgen INC. | $32.16 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $30.36 | 2019 | |
| Amag Pharmaceuticals, INC. | $30.15 | 2019 | |
| Gynesonics, INC. | $28.05 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Duchesnay USA Incorporated | $23.24 | 2020 | |
| Supernus Pharmaceuticals, INC. | $23.21 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $21.07 | 2021 | |
| Mayne Pharma Commercial LLC | $18.61 | 2023 | |
| Organon LLC | $11.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.